Ritter Pharmaceuticals announced additional findings and data from their Phase 2b/3 study of the company’s lead candidate RP-G28 in test subjects with lactose intolerance.
Ritter Pharmaceuticals (NASDAQ:RTTR) announced additional findings and data from their Phase 2b/3 study of the company’s lead candidate RP-G28 in test subjects with lactose intolerance.
As quoted in the press release:
These additional results from the trial analysis demonstrate that:
1. A clear drug effect was seen with significant positive reductions in key symptoms of lactose intolerance (LI) and across a variety of global and real world outcome measures.
2. The treatment effect suggests a clinically meaningful benefit to subjects in significantly reducing symptoms of lactose intolerance.
3. The study demonstrated safety with no serious adverse events related to treatment.
According to Andrew J. Ritter, President and co-founder of Ritter Pharmaceuticals, “As we continue to evaluate the results of this trial, we are increasingly excited by the strength of the data supporting RP-G28’s potentially significant and durable real-world treatment effect for patients suffering from lactose intolerance.”